Slide 1: On a mission to enhance the diagnosis of 100 million hearts
On a mission to enhance the diagnosis of 100 million hearts Helen Ljungdahl Round CEO May 2022 1
Slide 2: We all deserve to know immediately if our chest pain is related to heart disease
Acarix 2022: Rapid Market Expansion Peace of mind for We all deserve to know immediately if our chest pain is related to heart disease or not 2 – Introduction 2
Slide 3: More than 90% of patients with chest pain undergo multiple diagnostic tests
More than 90% of patients with 90-94% patients undergoing chest pain undergo multiple noninvasive testing diagnostic tests – for no reason do not suffer from CAD 1,2 Every day, approximately 1 million patients seek medical attention for chest pain related symptoms.1 Common symptoms affecting 20-40%
Slide 4: Acarix uses innovative acoustics and AI to rule out heart disease in minutes
Acarix uses innovative acoustics and AI to rule out heart disease in minutes Rule-out of CAD in less than 10 min with 96% confidence The novel CADScor®System enables non-invasive, AI-based rule-out of suspected CAD in patients with chest pain or shortness of breath Used on >8,000 patients with suspe
Slide 5: The NOVEL CADScor System for acoustic AI-based cardiac assessments
The NOVEL CADScor®System for acoustic AI-based cardiac assessments Ultra sensitive and intelligent AI-powered diagnostic aid, rooted in strong internationally renowned Danish audio engineering and academia Microphone for ambient noise cancelling Sensitive microphone Heart sound recording 5
Slide 6: The Acarix AI-powered unique algorithm for rapid detection of CAD
The Acarix AI-powered unique algorithm for rapid detection of CAD 0.1 0.05 0 -0.05 -0.1 20 20.5 21 21.5 22 22.5 23 23.5 24 24.5 25 Time (s) Segment heart sound recording into Noise reduction Feature extraction Classification heart beats 0.3 0.2 CAD-score >20 SysFRP Elevated risk of CAD 0.1 FRP Acous
Slide 7: CADScor System should be used early for maximum impact
CADScor®System should be used early for maximum impact Do CADScor®System first for early rule-out Patient with stable chest pain and suspected coronary artery disease (CAD) CCTA -Stress Invasive Invasive ECG Stress Echo MPI Nuclear Coronary Treatment Test via treadmill Imaging Angiography (PCI etc)
Slide 8: A clinical powerhouse in CAD detection with continued clinical development
A clinical powerhouse in CAD detection with continued clinical development Clinical trials overview (>8,000 patients) DAN-NICAD II ADOPT CAD BIO-CAC DAN-NICAD VALIDATE (2018-20) (2012-13) (2014-2015) (2014-16) (2016-17) AKUSTIK (2019-20) N = 228 N = 661 N = 1,675 N= 226 CAD Prevalence 28%* Technical
Slide 9: Early EU commercial validation completed – now in scale up phase
Early EU commercial validation completed – now in scale up phase +61% 150 CADScor®Systems in commercial use CE-marking and used in 7 markets with recurring sales and 75% gross margin Recent funding of net SEK 69 million to support US expansion +94% FDA De Novo clearance, approved CPT III Code and id
Slide 10: Attractive financial metrics
Attractive financial metrics Estimated Lifetime Value (LTV) of one delivered CADScor®System over 3 years: including use of disposable patches: • SEK 300,000 EU • USD 73,400 estimated US High potential US market • 20-40% lifetime prevalence of chest pain • >10.5 million visits to ED and outpatient cl
Slide 11: CADScor System is ideal for US market, meeting a clearly defined medical need
CADScor®System is ideal for US market, meeting a clearly defined medical need Reimbursement code New chest pain guidelines Large, patient driven covering CADScor®System opening new door billion $ US market AMA granted CADScor®System CPT III Any patient with pre-test probability Driving towards value
Slide 12: Structured US commercialization and expansion rapidly ongoing
Structured US commercialization and expansion rapidly ongoing Sales execution - Hybrid sales model including a direct sales team and sales agents in key regions, with IDNs, and VA. Sales partners targeting other channels and self funded employers' segment Positioning – Targeting Primary Care, Intern
Slide 13: Creating shareholder value – 2024 financial and operational targets
Creating shareholder value – 2024 financial and operational targets 2021/2022 Goals 2024 Goals ✓ New CEO and expanded team • Installed base of 3,000 CADScor®Systems with ✓ US expansion focus on US market ✓ Secured funding via new shares issue • Target revenue >SEK 200 M • Gross margin >80% Focus and
Slide 14: A strong team with international experience to make it happen
A strong team with international experience to make it happen Philip Siberg, Chair Marlou Janssen-Counotte, Board Co-founder/ex-CEO Coala Ex Medtronic, St Jude, Life, Chairman Senzime Biotronik Christian Lindholm, CFO Anders Krabbe, CCO Ex TFS Int, Doro Ex Novo Nordisk >25 years >25 years Helen Ljun
Slide 15: Summary: Why engage and invest in Acarix?
Summary Why engage and invest in Acarix? 1. Solid R&D, strong IP, regulatory approvals in place and strong comprehensive clinical data 2. Commercial model proven in EU, now expanding with reimbursement coverage in the US, the largest market and potential 3. Compelling financial metrics and a world-c
Slide 16: Thank you!
Thank you! Contact us CEO Helen Ljungdahl Round helen.round@acarix.com +46 (0)73 077 02 83 CFO Christian Lindholm christian.lindholm@acarix.com +46 (0)70 511 83 33 16